Objectives: The extent of whether staging by fluorodeoxyglucose positron-emission
tomography (PET) impacts outcomes in American Veterans with stage I-III non–small-cell …

Introduction Positron emission tomography (PET) has improved the accuracy of staging non-
small cell lung cancer (NSCLC), although some early-stage patients will still relapse. The …

Purpose Our objective was to determine the impact of initial 18 F-FDG PET/CT (PET/CT)
staging on clinical stage and the management plan and the prognostic value of PET/CT in …

7548 Background: Patients with stage III NSCLC are potentially curable using combined
modality therapy (CMT) with chemotherapy and radical radiation (RT). The use of PET-CT …

Purpose Previous studies have linked the use of positron emission tomography (PET) with
improved outcomes among patients with non–small-cell lung cancer (NSCLC). However …

Purpose Positron emission tomography (PET) is a costly new technology with potential to
improve preoperative evaluation for patients with non–small-cell lung cancer (NSCLC) …

Importance Positron emission tomography–computed tomography (PET-CT) has been
increasingly used in the management of lung cancer, but its association with survival has not …

Background: The application of positron emission tomography/computed tomography
(PET/CT) helps provide accurate clinical staging for lung cancer patients. However, the …

Purpose To study the impact of 18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET) on stage distribution and survival for patients with newly diagnosed non-small …

We investigated the incremental management impact and prognostic value of staging with
18F-FDG PET/CT in patients with non–small cell lung cancer (NSCLC) being considered for …